Barclays
RVMD icon

Barclays’s Revolution Medicines RVMD Stock Holding History

Barclays’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$806K – 5243
2024
Q1 		$806K Buy
+25,000
New +$741K ﹤0.01% 3284

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Barclays's RVMD Position: Q2 2026 in Review

Barclays reduced its Revolution Medicines (RVMD) stake by 71% in Q2 2026, selling an estimated $39.7M and leaving 111,178 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1111.

Barclays first reported a position in RVMD in Q1 2022 and has held it in 18 quarters since. The position peaked at $37.3M in Q1 2026. 692 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Barclays held 111,178 shares of Revolution Medicines worth $20.8M as of Q2 2026.
  • Barclays sold 272,001 Revolution Medicines shares in Q2 2026, an estimated $39.7M.
  • Revolution Medicines made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1111 holding.
  • Barclays first reported a position in Revolution Medicines in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Revolution Medicines position peaked at $37.3M in Q1 2026.
  • 692 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.